NEDL1 inhibitors pertain to a category of chemical compounds designed to selectively block or impede the activity of NEDL1 (Neural precursor cell Expressed Developmentally Down-regulated protein 4-like), which is a specific E3 ubiquitin ligase enzyme. E3 ubiquitin ligases are crucial components of the ubiquitin-proteasome system, responsible for regulating the degradation of proteins within cells. NEDL1, a member of the NEDD4-like family of E3 ligases, plays a role in the ubiquitination and subsequent degradation of target proteins. Inhibiting NEDL1 activity can have profound effects on protein turnover and cellular processes that rely on precise protein regulation.
Researchers use NEDL1 inhibitors as valuable tools in molecular biology and cell biology studies to elucidate the function of NEDL1 and its substrates. By selectively interfering with NEDL1 activity, scientists can investigate the impact on protein stability and degradation pathways. This, in turn, provides insights into the cellular functions and regulatory mechanisms controlled by NEDL1. Moreover, NEDL1 inhibitors can be used to explore the roles of NEDL1 in various biological processes, including cell signaling, protein homeostasis, and cell cycle regulation. Understanding the intricate details of NEDL1-mediated ubiquitination can have broad implications in deciphering the molecular basis of numerous diseases and cellular functions, thereby contributing to advancements in basic research.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A peptide aldehyde that inhibits the proteasome and could indirectly affect the stability and expression of E3 ligases like NEDL1. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that could impact E3 ligase function and expression by disrupting proteasomal degradation pathways. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
An irreversible proteasome inhibitor that could affect the expression of ubiquitin ligases through proteome-wide effects. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
An inhibitor of NEDD8-activating enzyme that could decrease the neddylation and activity of certain E3 ligases. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
An irreversible inhibitor of the ubiquitin-activating enzyme E1, potentially reducing the ubiquitination activity of ligases like NEDL1. | ||||||
IU1 | 314245-33-5 | sc-361215 sc-361215A sc-361215B | 10 mg 50 mg 100 mg | $138.00 $607.00 $866.00 | 2 | |
A specific inhibitor of USP14, a proteasome-associated deubiquitinase, which could affect ubiquitin ligase function indirectly. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Metabolite of lactacystin that acts as a proteasome inhibitor, possibly influencing ubiquitin ligase expression. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
A bioavailable proteasome inhibitor that could affect the activity and expression of E3 ligases. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
A selective proteasome inhibitor that may alter the expression of proteins involved in the ubiquitination pathway. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $130.00 $583.00 $4172.00 $20506.00 | 20 | |
A steroidal lactone that has been shown to inhibit proteasomal activity, potentially impacting E3 ligase function. | ||||||